BRAF/MEK/EGFR inhibitor combination

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BRAF/MEK/EGFR inhibitor combination, covering 2021-10-29 to 2021-10-29. Get the full timeline:

Most recent: Clinical Trial Update: BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) [Phase 1, Phase 2]